Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, Guggenheim Analyst Says

Key Points

• Guggenheim raised Merck’s price target to $171 from $170 and maintained a “buy” rating, implying 16.87% upside from the previous close.
• Merck reported strong quarterly results, with adjusted EPS of $2.49 beating the $2.09 consensus and revenue of $18.09 billion surpassing estimates. Analysts broadly remain positive, with a “Moderate Buy” consensus rating and an average price target of $153.16.
• Investors are weighing near-term momentum from KEYTRUDA, WINREVAIR and an improved outlook against longer-term risks from generic competition, the KEYTRUDA patent cliff and recent insider selling.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price objective upped by equities researchers at Guggenheim from $170.00 to $171.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's price objective would indicate a potential upside of 16.87% from the company's previous close.

Several other analysts also recently issued reports on the stock. Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a research report on Friday, September 4th. HSBC lifted their price target on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. UBS Group upped their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 20th. Scotiabank raised their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a "sector outperform" rating in a research note on Tuesday, September 29th. Finally, JPMorgan Chase & Co. lifted their target price on Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an "overweight" rating in a research report on Monday, October 5th. Seventeen investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of "Moderate Buy" and a consensus price target of $153.16.

Merck & Co., Inc. Trading Up 3.8%

Shares of MRK opened at $146.32 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The firm has a market capitalization of $360.99 billion, a P/E ratio of 117.05, a price-to-earnings-growth ratio of 6.49 and a beta of 0.21. The stock's fifty day simple moving average is $146.89 and its 200 day simple moving average is $126.49. Merck & Co., Inc. has a twelve month low of $82.01 and a twelve month high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the previous year, the business earned $2.58 earnings per share. The firm's quarterly revenue was up 4.7% compared to the same quarter last year. On average, equities research analysts forecast that Merck & Co., Inc. will post 2.64 earnings per share for the current year.

Insider Activity

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company's stock, valued at $6,073,631.14. This represents a 63.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Richard Deluca sold 20,784 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $130.43, for a total value of $2,710,857.12. Following the completion of the transaction, the executive vice president owned 134,703 shares of the company's stock, valued at $17,569,312.29. The trade was a 13.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 228,238 shares of company stock worth $29,977,783. Corporate insiders own 0.17% of the company's stock.

Hedge Funds Weigh In On Merck & Co., Inc.

Several large investors have recently bought and sold shares of MRK. Curry Webb Wealth Management LLC acquired a new position in Merck & Co., Inc. in the third quarter valued at about $29,000. Horizons Wealth Management acquired a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth about $30,000. Bullseye Investment Management LLC purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $27,000. Graney & King LLC boosted its stake in Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company's stock valued at $32,000 after acquiring an additional 200 shares in the last quarter. Finally, Foresight Capital Management Advisors Inc. purchased a new position in Merck & Co., Inc. during the 3rd quarter worth approximately $43,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported third-quarter adjusted earnings of $2.49 per share, well above the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, exceeding expectations of $17.33 billion. Merck third-quarter 2026 financial results
• Positive Sentiment: The company raised its 2026 adjusted profit outlook and projected full-year revenue of approximately $66.8 billion to $67.3 billion. A lower tax rate also helped support the improved earnings forecast. Merck boosts fiscal 2026 outlook
• Positive Sentiment: KEYTRUDA, including the newer QLEX formulation, delivered stronger-than-expected sales, while WINREVAIR continued to grow rapidly. These products are helping offset declines from older medicines and generic competition. Merck tops quarterly estimates
• Positive Sentiment: New cancer data provided additional pipeline support: KEYTRUDA reduced the risk of disease progression by 43% in a Phase 3 endometrial-cancer trial, while sacituzumab tirumotecan produced positive late-stage results and received FDA priority review. Merck endometrial cancer data and FDA review
• Neutral Sentiment: Management said new launches and WINREVAIR growth create momentum, but some reported revenue benefited from roughly $550 million in customer-purchase timing, implying underlying growth was more modest. Merck lifts outlook on lower tax rate
• Negative Sentiment: Investors remain concerned about generic headwinds in 2027 and the eventual KEYTRUDA patent cliff, which could pressure long-term revenue and earnings despite near-term operating strength. Merck earnings and Keytruda patent cliff
• Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to prior company disclosures. The announcement is not an allegation finding, but it adds headline and litigation risk. Merck securities investigation

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.